- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-269/15: Order of the General Court of 15 May 2019 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Vantobra — tobramycine — Withdrawal of the contested measure — Action which has become devoid of purpose — No need to adjudicate)
ECLI:EU:UNKNOWN:62015TB0269
62015TB0269
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
22.7.2019
Official Journal of the European Union
C 246/19
(Case T-269/15) (*)
(Medicinal products for human use - Marketing authorisation for the medicinal product Vantobra - tobramycine - Withdrawal of the contested measure - Action which has become devoid of purpose - No need to adjudicate)
(2019/C 246/19)
Language of the case: English
Parties
Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission (represented by: M. Šimerdová, A. Sipos and K. Mifsud-Bonnici, acting as Agents)
Intervener in support of the defendant: Pari Pharma GmbH (Starnberg, Germany) (represented by: M. Epping and W. Rehmann, lawyers)
Re:
Application based on Article 263 TFEU seeking annulment of Commission Implementing Decision C(2015) 1977 final of 18 March 2015 granting marketing authorisation for the medicinal product for human use Vantobra — tobramycine, in accordance with Regulation No 726/2004 of the European Parliament and of the Council,
Operative part of the order
1.There is no longer any need to adjudicate on the present action.
2.Novartis Europharm Ltd shall bear its own costs and pay those incurred by the European Commission.
3.Pari Pharma GmbH shall bear its own costs.
(*) Language of the case: English.
(1) OJ C 279, 24.8.2015.